-
公开(公告)号：US06949378B1
公开(公告)日：2005-09-27
申请号：US09513151
申请日：2000-02-25
IPC分类号： C07H21/04 , C07K14/435 , C12N5/10
CPC分类号： C07H21/04 , C07K14/43545
摘要： The invention relates to the identification of gro-1 gene and to demonstrate that the gro-1 gene is involved in the control of a central physiological clock. Also disclosed are four other genes located within the same operon as the gro-1 gene.
摘要翻译： 本发明涉及到gro-1基因的鉴定，并证明了gro-1基因参与了中枢生理钟的控制。 还公开了位于与gro-1基因相同的操纵子内的四个其它基因。
-
公开(公告)号：US20060024739A1
公开(公告)日：2006-02-02
申请号：US11237600
申请日：2005-09-27
IPC分类号： C12Q1/68 , C07H21/04 , C12P21/06 , C07K14/435
CPC分类号： C07H21/04 , C07K14/43545
摘要： The invention relates to the identification of gro-1 gene and to demonstrate that the gro-1 gene is involved in the control of a central physiological clock. Also disclosed are four other genes located within the same operon as the gro-1 gene.
摘要翻译： 本发明涉及到gro-1基因的鉴定，并证明了gro-1基因参与了中枢生理钟的控制。 还公开了位于与gro-1基因相同的操纵子内的四个其它基因。
-
3.发明申请Phenotypic effects of ubiquinone deficiencies and methods of screening thereof 审中-公开泛醌缺陷的表型作用及其筛选方法公开(公告)号：US20050039221A1
公开(公告)日：2005-02-17
申请号：US10486309
申请日：2002-08-07
IPC分类号： A01K67/027 , A01K67/033 , A61K49/00 , C12N5/10 , C12N9/02 , C12N9/10 , C12N15/09 , C12N15/85 , C12Q1/02 , C12Q1/26 , G01N33/50 , C12N5/06
CPC分类号： A01K67/0276 , A01K67/0336 , A01K2217/075 , A01K2227/105 , A01K2227/703 , A01K2267/03 , A61K49/0008 , C12N9/0073 , C12N9/1007 , C12N15/8509 , C12N2800/30 , G01N33/5085 , G01N33/5088 , G01N2500/00
摘要： The present invention relates to a method of screening for a compound allowing survival of clk1 homozygous mutant embryos; a method of screening for a compound suitable for rescue of mutant phenotype of mclk1 homozygous cell line; a method of screening for a compound suitable for partial or complete functional replacement of endogenous ubiquinone; a method for screening a compound capable of inhibiting activity of clk-1 and/or other processes required to make ubiquinone from demethoxyubiquinone; a non-ubiquinone-producer mouse; a DNA construct, which comprises an alteration of mclk1; a non-ubiquinone-producer ES cell line; a coq-3 mutant subject non-ubiquinone producer, a method of screening for a compound suitable for complete or partial functional ubiquinone or demethoxyubiquinone replacement; a method for reducing and/or increasing ubiquinone level in a multicellular subject; a method of screening for a genetic suppressor of clk-1; and a method of screening for a genetic suppressor of coq-3.
摘要翻译： 本发明涉及筛选能够使clk1纯合突变体胚存活的化合物的方法; 筛选适合拯救mclk1纯合子细胞系突变体表型的化合物的方法; 筛选适合部分或完全功能性替代内源泛醌的化合物的方法; 筛选能够抑制clk-1活性的化合物和/或从脱甲氧基泛醌制备泛醌所需的其它方法的方法; 非泛素生产小鼠; 包括mclk1的改变的DNA构建体; 非泛醌生产者ES细胞系; coq-3突变体受试者非泛醌生产者，筛选适用于完全或部分功能泛醌或脱甲氧基泛醌替代物的化合物的方法; 减少和/或增加多细胞受试者中泛醌水平的方法; 筛选clk-1的遗传抑制子的方法; 以及筛选coq-3的遗传抑制子的方法。
-
公开(公告)号：US07132274B2
公开(公告)日：2006-11-07
申请号：US10841316
申请日：2004-05-07
CPC分类号： G01N33/5014 , C12Q1/26 , G01N33/5008 , G01N33/5011 , G01N33/5017 , G01N33/502 , G01N33/5038
摘要： The present invention provides methods for screening modulators of 2-polyprenyl-3-methyl-6-methoxy-1,4-benzoquinone (DMQ) hydroxylation activity, inhibitors and activators of the activity, and methods of using such compounds. More particularly, this invention relates to modulators of and UbiF and CLK-1 enzyme activity and methods of identifying same.
摘要翻译： 本发明提供了筛选2-聚丙烯基-3-甲基-6-甲氧基-1,4-苯醌（DMQ）羟基化活性的调节剂的方法，该活性的抑制剂和活化剂以及使用这些化合物的方法。 更具体地，本发明涉及UbiF和CLK-1酶活性的调节剂及其鉴定方法。
-
5.发明申请Isolated clk-1 -/- cells from clk-1 heterozygous animals and their use in treating oxidative stress disorders 审中-公开来自clk-1杂合动物的分离的clk-1 - / - 细胞及其在治疗氧化应激障碍中的应用公开(公告)号：US20060088509A1
公开(公告)日：2006-04-27
申请号：US11245278
申请日：2005-10-06
申请人： Siegfried Hekimi , Xing Xing Liu , Ning Jiang , Eric Shoubridge
发明人： Siegfried Hekimi , Xing Xing Liu , Ning Jiang , Eric Shoubridge
IPC分类号： A61K35/407 , C12N5/08
CPC分类号： A61K35/48 , A01K67/0276 , A01K2217/075 , A01K2227/105 , A01K2267/03 , C12N5/0606 , C12N9/00 , C12N2517/02
摘要： The invention relates to the field of oxidative stress disorder and more specifically to isolated cells from clk-1 +/− animals that do not express CLK1. The invention also relates to methods for treating a subject or a diseased tissue in need of treatment for oxidative stress disorder using isolated clk-1 −/− cells from clk-1 +/− animals.
摘要翻译： 本发明涉及氧化应激障碍的领域，更具体地涉及不表达CLK1的clk-1 +/-动物的分离细胞。 本发明还涉及使用来自clk-1 +/-动物的分离的clk-1 - / - 细胞治疗需要治疗氧化应激障碍的受试者或患病组织的方法。
-
公开(公告)号：US20050019766A1
公开(公告)日：2005-01-27
申请号：US10484978
申请日：2002-07-26
申请人： Jinliu Feng , Frederic Bussiere , Siegfried Hekimi
发明人： Jinliu Feng , Frederic Bussiere , Siegfried Hekimi
IPC分类号： A61K38/00 , A61K38/16 , A61K38/17 , C07K14/395 , C07K14/415 , C07K14/435 , C07K14/465 , C07K14/47 , C07K14/80 , C12N9/02 , C12Q1/68 , C07H21/04 , C12N9/64
CPC分类号： C07K14/43536 , A61K38/00 , C07K14/395 , C07K14/415 , C07K14/465 , C07K14/47 , C07K14/80
摘要： The present invention relates to the characterization of mutants in the genes isp-1 and ctb-1, which are genes that have a function at the level of cellular physiology, mitochondrial respiration and electron transport, and resistance to oxidative stress, as well as regulating developmental, behavioral, reproductive and aging rates. Mutations in the genes isp-1 and ctb-1 are also provided. These genes and the protein they encode are used in a perspective of growth and aging control and in a therapeutic perspective for diseases in which mitochondrial function is altered. There is also provided methods of identification of compounds for the manipulation of the function of the isp-1 and ctb-1 genes and their protein products, as well as for the manipulation of the functions of mitochondria.
摘要翻译： 本发明涉及在基因isp-1和ctb-1中的突变体的表征，其是在细胞生理学，线粒体呼吸和电子传递以及抗氧化应激水平具有功能的基因以及调节 发育，行为，生殖和衰老率。 还提供了基因isp-1和ctb-1的突变。 这些基因及其编码的蛋白质以生长和老化控制的视角和治疗视角用于线粒体功能改变的疾病。 还提供了用于操作isp-1和ctb-1基因及其蛋白质产物的功能以及用于操纵线粒体功能的化合物的鉴定方法。
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.03 秒)
